All In Biotech

Drug Trial Radar · NCT00796653

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 937 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

937

Actual

Start

Jan 2009

Primary completion

Dec 2010

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Olodaterol (BI 1744)Drug

    Comparison of low and high doses on efficacy and safety in COPD patients

  • Olodaterol (BI 1744)Drug

    Comparison of low and high doses on efficacy and safety in COPD patients

  • FormoterolDrug

    Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients

  • PlaceboDrug

    Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 WeeksTime frame: 1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24
  2. Trough FEV1 Response at Week 24Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.
  3. Mahler Transitional Dyspnea Index Focal Score at 24 WeeksTime frame: Baseline, Week 24
  4. Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined AnalysisTime frame: Baseline, Week 24

Locations

98 sites in 20 countries. Site status is shown where the registry gives one.

  • 1222.14.5004 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1222.14.5003 Boehringer Ingelheim Investigational Site

    Mar del Plata, Argentina

  • 1222.14.5001 Boehringer Ingelheim Investigational Site

    Mendoza, Argentina

  • 1222.14.5002 Boehringer Ingelheim Investigational Site

    Quilmes, Argentina

  • 1222.14.5005 Boehringer Ingelheim Investigational Site

    San Juan Bautista, Argentina

  • 1222.14.5106 Boehringer Ingelheim Investigational Site

    Florianópolis, Brazil

  • 1222.14.5101 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 1222.14.5103 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 1222.14.5104 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 1222.14.5102 Boehringer Ingelheim Investigational Site

    Recife, Brazil

  • 1222.14.5105 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1222.14.4005 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1222.14.4002 Boehringer Ingelheim Investigational Site

    Kelowna, British Columbia, Canada

  • 1222.14.4004 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1222.14.4009 Boehringer Ingelheim Investigational Site

    Moncton, New Brunswick, Canada

  • 1222.14.4010 Boehringer Ingelheim Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • 1222.14.4008 Boehringer Ingelheim Investigational Site

    Grimsby, Ontario, Canada

  • 1222.14.4014 Boehringer Ingelheim Investigational Site

    Mississauga, Ontario, Canada

  • 1222.14.4007 Boehringer Ingelheim Investigational Site

    Newmarket, Ontario, Canada

  • 1222.14.4013 Boehringer Ingelheim Investigational Site

    Ottawa, Ontario, Canada

  • 1222.14.4001 Boehringer Ingelheim Investigational Site

    Scarborough Village, Ontario, Canada

  • 1222.14.4012 Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

  • 1222.14.4006 Boehringer Ingelheim Investigational Site

    Québec, Quebec, Canada

  • 1222.14.4015 Boehringer Ingelheim Investigational Site

    Sherbrooke, Quebec, Canada

  • 1222.14.4011 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan, Canada

  • 1222.14.6004 Boehringer Ingelheim Investigational Site

    Brno, Czechia

  • 1222.14.6003 Boehringer Ingelheim Investigational Site

    Hradec Králové, Czechia

  • 1222.14.6002 Boehringer Ingelheim Investigational Site

    Kyjov, Czechia

  • 1222.14.6001 Boehringer Ingelheim Investigational Site

    Znojmo, Czechia

  • 1222.14.4602 Boehringer Ingelheim Investigational Site

    Elsinore, Denmark

  • 1222.14.4601 Boehringer Ingelheim Investigational Site

    Hillerød, Denmark

  • 1222.14.4603 Boehringer Ingelheim Investigational Site

    Roskilde, Denmark

  • 1222.14.4702 Boehringer Ingelheim Investigational Site

    Espoo, Finland

  • 1222.14.4701 Boehringer Ingelheim Investigational Site

    HUS, Finland

  • 1222.14.4703 Boehringer Ingelheim Investigational Site

    Lohja, Finland

  • 1222.14.4106 Boehringer Ingelheim Investigational Site

    Aschaffenburg, Germany

  • 1222.14.4112 Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • 1222.14.4103 Boehringer Ingelheim Investigational Site

    Frankfurt, Germany

  • 1222.14.4110 Boehringer Ingelheim Investigational Site

    Frankfurt, Germany

  • 1222.14.4108 Boehringer Ingelheim Investigational Site

    Gelnhausen, Germany

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.